FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Goldman

Research Profile

Disorders

Chemicals & Drugs

Procedures

Anatomy

Co-author Network

Publications

TOP 3
John M Goldman
The Significance of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
John M Goldman; David Marin
Is imatinib still an acceptable first-line treatment for CML in chronic phase?
Sara Ali; Abdullah Alsuliman; Jane F Apperley; Richard E Clark; Nichola Cooper; Letizia Foroni; Ian H Gabriel; Gareth Gerrard; Maria Gilleece; John M Goldman; Corinne Hedgley; Ahmad Khoder; David Marin; Dragana Milojkovic; Stephen G O'Brien; Ruhena Sergeant; Kate Stringaris; K Rezvani
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Goldman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: John M Goldman
The Significance of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2013;19(5):679-80.
2012: John M Goldman; David Marin
Is imatinib still an acceptable first-line treatment for CML in chronic phase?
Oncology (Williston Park, N.Y.) 2012;26(10):901-7.
2012: Sara Ali; Abdullah Alsuliman; Jane F Apperley; Richard E Clark; Nichola Cooper; Letizia Foroni; Ian H Gabriel; Gareth Gerrard; Maria Gilleece; John M Goldman; Corinne Hedgley; Ahmad Khoder; David Marin; Dragana Milojkovic; Stephen G O'Brien; Ruhena Sergeant; Kate Stringaris; K Rezvani
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Blood 2012;120(3):697-8.
2012: David Marin; Dragana Milojkovic; Christopher Pocock; Jane Apperley; Richard E Clark; Letizia Foroni; John M Goldman; Corinne Hedgley; Stephen O'Brien
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Blood 2012;120(2):291-4.
2012: David Marin; Dragana Milojkovic; S O'Brien; R Sergeant; K Stringaris; H de Lavallade; S Ahmad; A Alsuliman; Jane F Apperley; Marco Bua; R Clark; N Cooper; J Davis; Letizia Foroni; I H Gabriel; John M Goldman; C Hedgley; A Khoder; Jamshid Sorouri Khorashad; K Rezvani
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Leukemia 2012;26(2):296-302.
2012: David Marin; Dragana Milojkovic; Christos Paliompeis; Jiri Pavlu; Alistair Reid; K Rezvani; Richard Szydlo; Lihui Wang; Jane F Apperley; Marco Bua; Richard E Clark; Gareth Gerrard; John M Goldman; Amr R Ibrahim; Claire Lucas; Letizia Foroni
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):232-8.
2011: David Marin; Amr R Ibrahim; John M Goldman
European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(29):3944-5.
2011: Hugues de Lavallade; Paula Garland; Takuya Sekine; Katja Hoschler; David Marin; Kate Stringaris; Eva Loucaides; Katherine Howe; Richard Szydlo; Ed Kanfer; Donald Macdonald; Peter Kelleher; Nichola Cooper; Ahmad Khoder; Ian H Gabriel; Dragana Milojkovic; Jiri Pavlu; John M Goldman; Jane F Apperley; K Rezvani
Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host.
Haematologica 2011;96(2):307-14.
2011: Jiri Pavlu; Richard Szydlo; John M Goldman; Jane F Apperley
Three decades of transplantation for chronic myeloid leukemia: what have we learned?
Blood 2011;117(3):755-63.
2010: Mustafa Daghistani; David Marin; Jamshid Sorouri Khorashad; Lihui Wang; Philippa C May; Christos Paliompeis; Dragana Milojkovic; Valeria A De Melo; Gareth Gerrard; John M Goldman; Jane F Apperley; Richard E Clark; Letizia Foroni; Alistair G Reid
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.
Blood 2010;116(26):6014-7.
2010: Amr R Ibrahim; Christos Paliompeis; Marco Bua; Dragana Milojkovic; Richard Szydlo; Jamshid Sorouri Khorashad; Letizia Foroni; Alistair Reid; Hugues de Lavallade; K Rezvani; Francesco Dazzi; Jane F Apperley; John M Goldman; David Marin
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Blood 2010;116(25):5497-500.
2010: A Bazeos; David Marin; A G Reid; Gareth Gerrard; D Milojkovic; P C May; Hugues de Lavallade; P Garland; K Rezvani; Jane F Apperley; John M Goldman; L Foroni; Jamshid Sorouri Khorashad
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Leukemia 2010;24(6):1243-5.
2010: Jirí Pavlů; Andrea K Kew; Beatrice Taylor-Roberts; Holger Auner; David Marin; Eduardo Olavarria; Edward J Kanfer; Donald H MacDonald; Dragana Milojkovic; Amin Rahemtulla; Katayoun Rezvani; John M Goldman; Jane F Apperley; Richard Szydlo
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase.
Blood 2010;115(20):4018-20.
2010: Dragana Milojkovic; Emma Nicholson; Jane F Apperley; Tessa L Holyoake; Pat Shepherd; Mark W Drummond; Richard Szydlo; Marco Bua; Letizia Foroni; Alistair Reid; Jamshid Sorouri Khorashad; Hugues de Lavallade; K Rezvani; Christos Paliompeis; John M Goldman; David Marin
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Haematologica 2010;95(2):224-31.
2009: John M Goldman; A R Green; T Holyoake; C Jamieson; R Mesa; T Mughal; F Pellicano; D Perrotti; R Skoda; A M Vannucchi
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Leukemia 2009;23(10):1708-15.
2009: John M Goldman
Treatment strategies for CML.
Best practice & research. Clinical haematology 2009;22(3):303-13.
2009: David Marin; Jamshid Sorouri Khorashad; Letizia Foroni; Dragana Milojkovic; Richard Szydlo; Alistair G Reid; K Rezvani; Marco Bua; John M Goldman; Jane F Apperley
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
British journal of haematology 2009;145(3):373-5.
2009: Agnes S M Yong; Keyvan Keyvanfar; Nancy Hensel; Rhoda Eniafe; Bipin N Savani; Maria Berg; Andreas Lundqvist; Sharon Adams; Elaine M Sloand; John M Goldman; Richard Childs; A John Barrett
Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Blood 2009;113(4):875-82.
2008: David Marin; Dragana Milojkovic; Eduardo Olavarria; Jamshid Sorouri Khorashad; Hugues de Lavallade; Alistair G Reid; Letizia Foroni; K Rezvani; Marco Bua; Francesco Dazzi; Jiri Pavlu; Matthias Klammer; Jaspal Kaeda; John M Goldman; Jane F Apperley
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Blood 2008;112(12):4437-44.
2008: Jamshid Sorouri Khorashad; Hugues de Lavallade; Jane F Apperley; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4806-13.
2008: Mohamad Mohty; Richard Szydlo; Agnes S M Yong; Jane F Apperley; John M Goldman; Junia V Melo
Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.
Blood 2008;112(5):2163-6.
2008: Agnes S M Yong; Keyvan Keyvanfar; Rhoda Eniafe; Bipin N Savani; Katayoun Rezvani; Elaine M Sloand; John M Goldman; A John Barrett
Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Leukemia 2008;22(9):1721-7.
2008: Hugues de Lavallade; Jane F Apperley; Jamshid Sorouri Khorashad; Dragana Milojkovic; Alistair G Reid; Marco Bua; Richard Szydlo; Eduardo Olavarria; Jaspal Kaeda; John M Goldman; David Marin
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(20):3358-63.
2008: Jamshid Sorouri Khorashad; N Thelwell; D Milojkovic; D Marin; J A Watson; John M Goldman; J F Apperley; L Foroni; A G Reid
A new rapid and sensitive assay for detecting the T315I BCR-ABL kinase domain mutation in chronic myeloid leukaemia.
Journal of clinical pathology 2008;61(7):863-5.
2008: Hugues de Lavallade; Sinthiya Punnialingam; Dragana Milojkovic; Marco Bua; Jamshid Sorouri Khorashad; Ian H Gabriel; Aristeidis Chaidos; Eduardo Olavarria; John M Goldman; Jane F Apperley; David Marin
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
British journal of haematology 2008;141(5):745-7.
2008: Jamshid Sorouri Khorashad; Dragana Milojkovic; Puja Mehta; Mona Anand; Sara Ghorashian; Alistair G Reid; Valeria De Melo; Anna Babb; Hugues de Lavallade; Eduardo Olavarria; David Marin; John M Goldman; Jane F Apperley; Jaspal Kaeda
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Blood 2008;111(4):2378-81.
2008: John M Goldman; Junia V Melo
BCR-ABL in chronic myelogenous leukemia--how does it work?
Acta haematologica 2008;119(4):212-7.
2007: Eduardo Olavarria; Shamyla Siddique; Michael J Griffiths; Sharon Avery; Jenny L Byrne; Karen P Piper; Anne L Lennard; Lalit Pallan; Julie Arrazi; Jolanta B Perz; Derville O'Shea; John M Goldman; Jane F Apperley; Charles Craddock
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Blood 2007;110(13):4614-7.
2007: Valeria A S De Melo; Dragana Milojkovic; Jamshid Sorouri Khorashad; David Marin; John M Goldman; Jane F Apperley; Alistair G Reid
Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia.
Blood 2007;110(8):3086-7.
2007: John M Goldman
How I treat chronic myeloid leukemia in the imatinib era.
Blood 2007;110(8):2828-37.
2007: Hugues de Lavallade; Jamshid Sorouri Khorashad; Howard P Davis; Dragana Milojkovic; Jaspal Kaeda; John M Goldman; Jane F Apperley; David Marin
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
Blood 2007;110(7):2779-80.
2007: Agnes S M Yong; Katayoun Rezvani; Bipin N Savani; Rhoda Eniafe; Stephan Mielke; John M Goldman; A John Barrett
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Blood 2007;110(2):770-5.
2007: Jiri Pavlu; Catharina Andreasson; Charles Chuah; Jaspal Kaeda; John M Goldman; Jane F Apperley; David Marin
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
British journal of haematology 2007;137(5):423-8.
2007: M P Simula; Sarah Marktel; Claudio Fozza; Jaspal Kaeda; Richard Szydlo; Elisabet Nadal; Marco Bua; Amin Rahemtulla; Edward Kanfer; David Marin; Eduardo Olavarria; John M Goldman; Jane F Apperley; Francesco Dazzi
Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy.
Leukemia 2007;21(5):943-8.
2007: Tariq I Mughal; John M Goldman
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S95-101.
2007: Tariq I Mughal; John M Goldman
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S81-4.
2007: Claudio Fozza; Richard Szydlo; M M Abdel-Rehim; Elisabet Nadal; John M Goldman; Jane F Apperley; Francesco Dazzi
Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose.
British journal of haematology 2007;136(6):833-6.
2007: Marianna David; Nicholas C P Cross; Sonja Burgstaller; Andrew Chase; Claire Curtis; Raymond Dang; Martine Gardembas; John M Goldman; Francis H Grand; George Hughes; Francoise Huguet; Louise Lavender; Grant A McArthur; François-Xavier Mahon; Giorgio Massimini; Junia Melo; Philippe Rousselot; Robin J Russell-Jones; John F Seymour; Graeme Smith; Alastair Stark; Katherine Waghorn; Zariana Nikolova; Jane F Apperley
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
Blood 2007;109(1):61-4.
2006: Tariq I Mughal; John M Goldman
Targeting cancers with tyrosine kinase inhibitors: lessons learned from chronic myeloid leukaemia.
Clinical medicine (London, England) 2006;6(6):526-8.
2006: Mona Anand; Jamshid Sorouri Khorashad; David Marin; Jane F Apperley; John M Goldman; Jaspal Kaeda
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Blood 2006;108(8):2881-2.
2006: Jaspal Kaeda; Derville O'Shea; Richard Szydlo; Eduardo Olavarria; Francesco Dazzi; David Marin; Susan Saunders; Jamshid Sorouri Khorashad; Nicholas C P Cross; John M Goldman; Jane F Apperley
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
Blood 2006;107(10):4171-6.
2006: Jamshid Sorouri Khorashad; M Anand; David Marin; S Saunders; T Al-Jabary; A Iqbal; S Margerison; J V Melo; John M Goldman; Jane F Apperley; Jaspal Kaeda
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Leukemia 2006;20(4):658-63.
2006: Tariq I Mughal; John M Goldman
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Frontiers in bioscience : a journal and virtual library 2006;11():209-20.
2006: Tariq I Mughal; John M Goldman
Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?
Frontiers in bioscience : a journal and virtual library 2006;11():198-208.
2006: Agnes S M Yong; Richard Szydlo; John M Goldman; Jane F Apperley; Junia V Melo
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Blood 2006;107(1):205-12.
2005: David J Barnes; Danai Palaiologou; Eleni Panousopoulou; Beate Schultheis; Agnes S M Yong; Alice Wong; Laura Pattacini; John M Goldman; Junia V Melo
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Cancer research 2005;65(19):8912-9.
2005: David Marin; Jaspal Kaeda; Catharina Andreasson; Sue M Saunders; Marco Bua; Eduardo Olavarria; John M Goldman; Jane F Apperley
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Cancer 2005;103(9):1850-5.
2005: John M Goldman
A unifying mutation in chronic myeloproliferative disorders.
The New England journal of medicine 2005;352(17):1744-6.
2005: David Marin; Jaspal Kaeda; Richard Szydlo; S Saunders; A Fleming; J Howard; Catharina Andreasson; Marco Bua; Eduardo Olavarria; Amin Rahemtulla; Francesco Dazzi; Edward Kanfer; John M Goldman; Jane F Apperley
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Leukemia 2005;19(4):507-12.
2004: Evangelos Terpos; Marianna Politou; Richard Szydlo; Elisabet Nadal; S Avery; Eduardo Olavarria; Edward Kanfer; John M Goldman; Jane F Apperley; Amin Rahemtulla
Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.
Leukemia 2004;18(8):1420-6.
2004: Alex J Tipping; S Baluch; David J Barnes; Darren R Veach; B M Clarkson; William G Bornmann; François-Xavier Mahon; John M Goldman; Junia V Melo
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Leukemia 2004;18(8):1352-6.
2004: Tariq I Mughal; John M Goldman
Chronic myeloid leukemia: current status and controversies.
Oncology (Williston Park, N.Y.) 2004;18(7):837-44, 847; discussion 847-50, 853-4.
2004: S Avery; Elisabet Nadal; David Marin; Eduardo Olavarria; Jaspal Kaeda; Tom Vulliamy; F Brito Babapulle; John M Goldman; Jane F Apperley
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Leukemia research 2004;28 Suppl 1():S75-7.
2004: William J Jordan; Paul A Brookes; Richard Szydlo; John M Goldman; Robert I Lechler; Mary A Ritter
IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation.
Blood 2004;103(2):717-24.
2004: John M Goldman
Chronic myeloid leukemia-still a few questions.
Experimental hematology 2004;32(1):2-10.
2003: Alex J Tipping; Michael W N Deininger; John M Goldman; Junia V Melo
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Experimental hematology 2003;31(11):1073-80.
2003: John M Goldman; Junia V Melo
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
The New England journal of medicine 2003;349(15):1451-64.
2003: John M Goldman
Myeloproliferative and myelodysplastic syndromes: the future.
Hematology/oncology clinics of North America 2003;17(5):1261-9.
2003: Evangelos Terpos; Marianna Politou; Richard Szydlo; John M Goldman; Jane F Apperley; Amin Rahemtulla
Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
British journal of haematology 2003;123(1):106-9.
2003: Evangelos Terpos; Josu de la Fuente; Richard Szydlo; Evdoxia Hatjiharissi; Nora Viniou; John Meletis; Xenophon Yataganas; John M Goldman; Amin Rahemtulla
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
International journal of cancer. Journal international du cancer 2003;106(3):455-7.
2003: David Marin; Sarah Marktel; Richard Szydlo; John P Klein; Marco Bua; Nicola Foot; Eduardo Olavarria; Pat Shepherd; Edward Kanfer; John M Goldman; Jane F Apperley
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Lancet 2003;362(9384):617-9.
2003: David Marin; Sarah Marktel; Marco Bua; Richard Szydlo; A Franceschino; I Nathan; Nicola Foot; Charles Crawley; T Na Nakorn; Eduardo Olavarria; Anne Lennard; A Neylon; S G O'Brien; John M Goldman; Jane F Apperley
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
Leukemia 2003;17(8):1448-53.
2003: Myrtle Y Gordon; Stephen B Marley; Jane F Apperley; David Marin; Jaspal Kaeda; Richard Szydlo; John M Goldman
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.
British journal of haematology 2003;122(3):424-9.
2003: Evangelos Terpos; Richard Szydlo; Jane F Apperley; Evdoxia Hatjiharissi; Marianna Politou; John Meletis; Nora Viniou; Xenophon Yataganas; John M Goldman; Amin Rahemtulla
Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.
Blood 2003;102(3):1064-9.
2003: Rong Dong; Kate Cwynarski; Alan Entwistle; Federica M Marelli-Berg; Francesco Dazzi; Elizabeth Simpson; John M Goldman; Junia V Melo; Robert I Lechler; Ilaria Bellantuono; Anne Ridley; Giovanna Lombardi
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Blood 2003;101(9):3560-7.
2003: John M Goldman; David Marin; Eduardo Olavarria; Jane F Apperley
Clinical decisions for chronic myeloid leukemia in the imatinib era.
Seminars in hematology 2003;40(2 Suppl 2):98-103; discussion 104-13.
2003: François-Xavier Mahon; Francis Belloc; Valérie Lagarde; Claudine Chollet; François Moreau-Gaudry; Josy Reiffers; John M Goldman; Junia V Melo
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Blood 2003;101(6):2368-73.
2003: Sarah Marktel; David Marin; Nicola Foot; Richard Szydlo; Marco Bua; Anastasios Karadimitris; Valeria A S De Melo; Paul Kotzampaltiris; Francesco Dazzi; Amin Rahemtulla; Eduardo Olavarria; Jane F Apperley; John M Goldman
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Haematologica 2003;88(3):260-7.
2003: Evangelos Terpos; Jane F Apperley; D Samson; Chrissy Giles; Charles Crawley; Edward Kanfer; Eduardo Olavarria; John M Goldman; Amin Rahemtulla
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Bone marrow transplantation 2003;31(3):163-70.
2003: David Marin; Sarah Marktel; Nicola Foot; Marco Bua; John M Goldman; Jane F Apperley
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Haematologica 2003;88(2):227-9.
2003: Persis J Amrolia; Steven D Reid; Liquan Gao; Beate Schultheis; Gianpietro Dotti; Malcolm K Brenner; Junia V Melo; John M Goldman; Hans J Stauss
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Blood 2003;101(3):1007-14.
2003: Evangelos Terpos; Nora Viniou; Josu de la Fuente; John Meletis; Ersi Voskaridou; Christos Karkantaris; George Vaiopoulos; John Palermos; Xenophon Yataganas; John M Goldman; Amin Rahemtulla
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
European journal of haematology 2003;70(1):34-42.
2003: John M Goldman; David Marin
Management decisions in chronic myeloid leukemia.
Seminars in hematology 2003;40(1):97-103.
2002: Faris Q Alenzi; Stephen B Marley; John L Lewis; Anil Chandrashekran; Anthony N Warrens; John M Goldman; Myrtle Y Gordon
A role for the Fas/Fas ligand apoptotic pathway in regulating myeloid progenitor cell kinetics.
Experimental hematology 2002;30(12):1428-35.
2002: Alex J Tipping; François-Xavier Mahon; GEORGE ZAFIRIDES; Valérie Lagarde; John M Goldman; Junia V Melo
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Leukemia 2002;16(12):2349-57.
2002: Ilaria Bellantuono; Liquan Gao; Suzanne Parry; Stephen B Marley; Francesco Dazzi; Jane Apperley; John M Goldman; Hans J Stauss
Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL.
Blood 2002;100(10):3835-7.
2002: Christophe Barthe; Marie-Josée Gharbi; Valérie Lagarde; Claudine Chollet; Pascale Cony-Makhoul; Josy Reiffers; John M Goldman; Junia V Melo; François-Xavier Mahon
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
British journal of haematology 2002;119(1):109-11.
2002: David Marin; Sarah Marktel; Marco Bua; Lorraine Armstrong; John M Goldman; Jane F Apperley; Eduardo Olavarria
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Haematologica 2002;87(9):979-88.
2002: Eduardo Olavarria; Josy Reiffers; Concha Boque; Ana Sureda; Giovanna Meloni; Mauricette Michallet; Richard E Clark; Didier Blaise; Angelo M Carella; Jean-Yves Cahn; Jean P Jouet; Vittorio Rizzoli; Anja van Biezen; Alois Gratwohl; John M Goldman; Dietger Niederwieser; Jane F Apperley
The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase.
British journal of haematology 2002;118(3):762-70.
2002: Jane F Apperley; Martine Gardembas; Junia V Melo; Robin Russell-Jones; Barbara J Bain; E Joanna Baxter; Andrew Chase; Judith M Chessells; Marie Colombat; Claire E Dearden; Sasa Dimitrijevic; François-Xavier Mahon; David Marin; Zariana Nikolova; Eduardo Olavarria; Sandra Silberman; Beate Schultheis; Nicholas C P Cross; John M Goldman
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
The New England journal of medicine 2002;347(7):481-7.
2002: Eduardo Olavarria; Charles Craddock; Francesco Dazzi; David Marin; Sarah Marktel; Jane F Apperley; John M Goldman
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Blood 2002;99(10):3861-2.
2002: Jyoti Wadhwa; Richard Szydlo; Jane F Apperley; Andrew Chase; Marco Bua; David Marin; Eduardo Olavarria; Edward Kanfer; John M Goldman
Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia.
Blood 2002;99(7):2304-9.
2002: Beate Schultheis; Melina Carapeti-Marootian; Andreas Hochhaus; Andreas Weisser; John M Goldman; Junia V Melo
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Blood 2002;99(5):1766-75.
2002: Jaspal Kaeda; Andrew Chase; John M Goldman
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Acta haematologica 2002;107(2):64-75.
2002: Stephen B Marley; R John Davidson; John M Goldman; Myrtle Y Gordon
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
British journal of haematology 2002;116(1):162-5.
2001: Alex J Tipping; François-Xavier Mahon; Valérie Lagarde; John M Goldman; Junia V Melo
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.
Blood 2001;98(13):3864-7.
2001: A Demiroglu; E J Steer; C Heath; Kerry Taylor; Mark Bentley; Steven Allen; Prasad R K Koduru; JP Brody; G Hawson; Robyn Rodwell; M L Doody; F Carnicero; A Reiter; John M Goldman; Junia V Melo; Nicholas C P Cross
The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.
Blood 2001;98(13):3778-83.
2001: S A Vieira; Michael W N Deininger; A Sorour; Paul Sinclair; Letizia Foroni; John M Goldman; Junia V Melo
Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene.
Genes, chromosomes & cancer 2001;32(4):353-63.
2001: Tariq I Mughal; Agnes S M Yong; Richard Szydlo; Francesco Dazzi; Eduardo Olavarria; F van Rhee; Jaspal Kaeda; Nicholas C P Cross; Charles Craddock; Edward Kanfer; Jane Apperley; John M Goldman
Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.
British journal of haematology 2001;115(3):569-74.
2001: Michael W N Deininger; S A Vieira; Y Parada; Lolita Banerji; Eric W-F Lam; G Peters; François-Xavier Mahon; T Köhler; John M Goldman; Junia V Melo
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Cancer research 2001;61(21):8005-13.
2001: Stephen B Marley; R John Davidson; John L Lewis; DX Nguyen; A Eades; S Parker; John M Goldman; Myrtle Y Gordon
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.
Leukemia research 2001;25(11):997-1002.
2001: John M Goldman; Brian J Druker
Chronic myeloid leukemia: current treatment options.
Blood 2001;98(7):2039-42.
2001: J Sohal; Andrew Chase; Sarah Mould; Martin Corcoran; David Oscier; S Iqbal; S Parker; Jeanna Welborn; R I Harris; giovanni martinelli; V Montefusco; Paul Sinclair; B S Wilkins; H van den Berg; D Vanstraelen; John M Goldman; Nicholas C P Cross
Identification of four new translocations involving FGFR1 in myeloid disorders.
Genes, chromosomes & cancer 2001;32(2):155-63.
2001: Kate Cwynarski; R Goulding; CF Pocock; Francesco Dazzi; Charles Craddock; Jaspal Kaeda; Eduardo Olavarria; Edward Kanfer; Jane Apperley; M Lawler; John M Goldman
Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions.
Bone marrow transplantation 2001;28(6):581-6.
2001: Junia V Melo; A Kumberova; A G van Dijk; John M Goldman; M R Yuille
Investigation on the role of the ATM gene in chronic myeloid leukaemia.
Leukemia 2001;15(9):1448-50.
2001: Francesco Dazzi; Elizabeth Simpson; John M Goldman
Minor antigen solves major problem.
Nature medicine 2001;7(7):769-70.
2001: CF Pocock; G F Lucas; C Giles; G Vassiliou; Kate Cwynarski; K Rezvani; Jane F Apperley; John M Goldman
Immune neutropenia associated with anti-human neutrophil antigen-2a (NB1) antibodies following unrelated donor stem cell transplantation for chronic myeloid leukaemia: perpetuation by granulocyte colony-stimulating factor.
British journal of haematology 2001;113(2):483-5.
2001: John L Lewis; W Chinswangwatanakul; B Zheng; Stephen B Marley; DX Nguyen; Nicholas C P Cross; Lolita Banerji; Janet Glassford; N Shaun B Thomas; John M Goldman; Eric W-F Lam; Myrtle Y Gordon
The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells.
Blood 2001;97(9):2604-10.
2001: Eduardo Olavarria; Edward Kanfer; Richard Szydlo; Jaspal Kaeda; K Rezvani; Kate Cwynarski; CF Pocock; Francesco Dazzi; Charles Craddock; Jane F Apperley; Nicholas C P Cross; John M Goldman
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood 2001;97(6):1560-5.
2001: Tariq I Mughal; John M Goldman
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
European journal of cancer (Oxford, England : 1990) 2001;37(5):561-8.
2001: Stephen B Marley; John L Lewis; B Zheng; R John Davidson; J G Davis; C McDonald; Faris Q Alenzi; John M Goldman; Myrtle Y Gordon
Peripheral blood progenitor cell mobilisation alters myeloid, but not erythroid, progenitor cell self-renewal kinetics.
Bone marrow transplantation 2001;27(3):241-8.
2001: Charles Craddock; Richard Szydlo; Francesco Dazzi; Eduardo Olavarria; Kate Cwynarski; Agnes S M Yong; Paul A Brookes; J de la Fuente; Edward Kanfer; Jane F Apperley; John M Goldman
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis.
British journal of haematology 2001;112(1):228-36.
2000: Francesco Dazzi; Richard Szydlo; Nicholas C P Cross; Charles Craddock; Jaspal Kaeda; Edward Kanfer; Kate Cwynarski; Eduardo Olavarria; Agnes S M Yong; Jane F Apperley; John M Goldman
Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Blood 2000;96(8):2712-6.
2000: Stephen B Marley; R John Davidson; John M Goldman; Myrtle Y Gordon
Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM.
Leukemia 2000;14(8):1396-400.
2000: François-Xavier Mahon; Michael W N Deininger; Beate Schultheis; J Chabrol; J Reiffers; John M Goldman; Junia V Melo
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Blood 2000;96(3):1070-9.
2000: Shashikant Kulkarni; C Heath; S Parker; Andrew Chase; S Iqbal; CF Pocock; Jaspal Kaeda; Kate Cwynarski; John M Goldman; Nicholas C P Cross
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR-ABL-negative myeloproliferative disorders with a t(5;10)(q33;q21).
Cancer research 2000;60(13):3592-8.
2000: Charles Craddock; Richard Szydlo; J P Klein; Francesco Dazzi; Eduardo Olavarria; F van Rhee; CF Pocock; Kate Cwynarski; Jane F Apperley; John M Goldman
Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission.
Blood 2000;96(1):86-90.
2000: Eduardo Olavarria; S Parker; Charles Craddock; N Philpott; M Tiniakou; Andrew Chase; Edward Kanfer; Jane F Apperley; John M Goldman
Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization.
Haematologica 2000;85(6):647-52.
2000: S Iqbal; David Grimwade; A Chase; Anthony Goldstone; Alan Burnett; John M Goldman; David M Swirsky
Identification of PML/RARalpha rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. MRC Adult Leukaemia Working Party.
Leukemia 2000;14(5):950-3.
2000: Michael W N Deininger; S Vieira; R Mendiola; Beate Schultheis; John M Goldman; Junia V Melo
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
Cancer research 2000;60(7):2049-55.
2000: L Gao; Ilaria Bellantuono; A Elsässer; Stephen B Marley; Myrtle Y Gordon; John M Goldman; Hans J Stauss
Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1.
Blood 2000;95(7):2198-203.
2000: John M Goldman
Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia.
Lancet 2000;355(9209):1031-2.
2000: Andrew Chase; J Pickard; Richard Szydlo; S Coulthard; John M Goldman; Nicholas C P Cross
Non-random involvement of chromosome 13 in patients with persistent or relapsed disease after bone-marrow transplantation for chronic myeloid leukemia.
Genes, chromosomes & cancer 2000;27(3):278-84.
2000: Francesco Dazzi; Robert P Hasserjian; Myrtle Y Gordon; F Boecklin; Finbarr E Cotter; M Corbo; D Capelli; John M Goldman
Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(5):307-15.
2000: Myrtle Y Gordon; Stephen B Marley; R John Davidson; Francis H Grand; John L Lewis; DX Nguyen; S Lloyd; John M Goldman
Contact-mediated inhibition of human haematopoietic progenitor cell proliferation may be conferred by stem cell antigen, CD34.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(2):77-86.
2000: J Sohal; A Reiter; John M Goldman; Nicholas C P Cross
Cloning of ZNF237, a novel member of the MYM gene family that maps to human chromosome 13q11-->q12.
Cytogenetics and cell genetics 2000;89(1-2):24-8.
2000: P Konstantinidou; Richard Szydlo; Andrew Chase; John M Goldman
Cytogenetic status pre-transplant as a predictor of outcome post bone marrow transplantation for chronic myelogenous leukaemia.
Bone marrow transplantation 2000;25(2):143-6.
2000: Francesco Dazzi; Richard Szydlo; Charles Craddock; Nicholas C P Cross; Jaspal Kaeda; Andrew Chase; Eduardo Olavarria; F van Rhee; Edward Kanfer; Jane F Apperley; John M Goldman
Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.
Blood 2000;95(1):67-71.
1999: E Garrett; Marina I Garin; A R Miller; John M Goldman; Junia V Melo; Jane F Apperley
Enhanced retroviral gene transfer into CML and normal bone marrow, and CML and mobilized peripheral blood CD34+ cells using the recombinant fibronectin fragment CH-296.
British journal of haematology 1999;107(2):401-8.
1999: Francesco Dazzi; Richard Szydlo; John M Goldman
Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.
Experimental hematology 1999;27(10):1477-86.
1999: Francis H Grand; Shashikant Kulkarni; Andrew Chase; John M Goldman; M Gordon; Nicholas C P Cross
Frequent deletion of hSNF5/INI1, a component of the SWI/SNF complex, in chronic myeloid leukemia.
Cancer research 1999;59(16):3870-4.
1999: M Carapeti; Ricardo Aguiar; Ann Watmore; John M Goldman; Nicholas C P Cross
Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13).
Cancer genetics and cytogenetics 1999;113(1):70-2.
1999: Stephen B Marley; John L Lewis; R John Davidson; Irene A G Roberts; Inderjeet Dokal; John M Goldman; Myrtle Y Gordon
Evidence for a continuous decline in haemopoietic cell function from birth: application to evaluating bone marrow failure in children.
British journal of haematology 1999;106(1):162-6.
1999: DH Macdonald; D Lahiri; Andrew Chase; J Sohal; John M Goldman; Nicholas C P Cross
A case of myelofibrosis with a t(4;13)(q25;q12): evidence for involvement of a second 13q12 locus in chronic myeloproliferative disorders.
British journal of haematology 1999;105(3):771-4.
1999: Myrtle Y Gordon; Francesco Dazzi; Stephen B Marley; John L Lewis; D Nguyen; Francis H Grand; R John Davidson; John M Goldman
Cell biology of CML cells.
Leukemia 1999;13 Suppl 1():S65-71.
1999: Raffaella Stocchi; Richard Szydlo; Charles Craddock; Edward Kanfer; Jane F Apperley; John M Goldman; K N Ward
A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation.
Bone marrow transplantation 1999;23(7):705-9.
1999: Andrew Chase; A Reiter; L Burci; Giovanni Cazzaniga; A Biondi; J Pickard; Irene A G Roberts; John M Goldman; Nicholas C P Cross
Fusion of ETV6 to the caudal-related homeobox gene CDX2 in acute myeloid leukemia with the t(12;13)(p13;q12).
Blood 1999;93(3):1025-31.
1999: J Sohal; Andrew Chase; John M Goldman; Nicholas C P Cross
Assignment of ZNF262 to human chromosome band 1p34-->p32 by in situ hybridization.
Cytogenetics and cell genetics 1999;85(3-4):306-7.
1999: A A Shlebak; Stephen B Marley; Irene A G Roberts; R John Davidson; John M Goldman; Myrtle Y Gordon
Optimal timing for processing and cryopreservation of umbilical cord haematopoietic stem cells for clinical transplantation.
Bone marrow transplantation 1999;23(2):131-6.
1999: A Spencer; Richard Szydlo; Francis H Grand; John M Goldman; J V Melo
Abnormal patterns of immunoglobulin heavy chain gene DNA fingerprinting during chronic phase chronic myeloid leukemia.
Leukemia & lymphoma 1999;32(3-4):299-307.
1999: S Kulkarni; A Reiter; D Smedley; John M Goldman; Nicholas C P Cross
The genomic structure of ZNF198 and location of breakpoints in the t(8;13) myeloproliferative syndrome.
Genomics 1999;55(1):118-21.
1998: A A Shlebak; Irene A G Roberts; T A Stevens; R M Syzdlo; John M Goldman; Myrtle Y Gordon
The impact of antenatal and perinatal variables on cord blood haemopoietic stem/progenitor cell yield available for transplantation.
British journal of haematology 1998;103(4):1167-71.
1998: J Gora-Tybor; Michael W N Deininger; John M Goldman; Junia V Melo
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
British journal of haematology 1998;103(3):716-20.
1998: S Bose; Michael W N Deininger; J Gora-Tybor; John M Goldman; Junia V Melo
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
Blood 1998;92(9):3362-7.
1998: J F Apperley; Francesco Dazzi; Charles Craddock; John M Goldman
Immunotherapy for chronic myeloid leukaemia.
Hematology and cell therapy 1998;40(5):229-32.
1998: Francis H Grand; Andrew Chase; S Iqbal; DX Nguyen; John L Lewis; Stephen B Marley; R John Davidson; John M Goldman; Myrtle Y Gordon
A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
Genes, chromosomes & cancer 1998;23(2):109-15.
1998: M Carapeti; Ricardo Aguiar; Andrew Chase; John M Goldman; Nicholas C P Cross
Assignment of the steroid receptor coactivator-1 (SRC-1) gene to human chromosome band 2p23.
Genomics 1998;52(2):242-4.
1998: A Reiter; Stephen B Marley; A Hochhaus; J Sohal; Pia Raanani; R Hehlmann; Myrtle Y Gordon; John M Goldman; Nicholas C P Cross
BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
British journal of haematology 1998;102(5):1271-8.
1998: M Carapeti; Ricardo Aguiar; Heinz Sill; John M Goldman; Nicholas C P Cross
Aberrant transcripts of the FHIT gene are expressed in normal and leukaemic haemopoietic cells.
British journal of cancer 1998;78(5):601-5.
1998: A Reiter; J Sohal; Shashikant Kulkarni; Andrew Chase; DH Macdonald; Ricardo Aguiar; C Gonçalves; J M Hernandez; B A Jennings; John M Goldman; Nicholas C P Cross
Consistent fusion of ZNF198 to the fibroblast growth factor receptor-1 in the t(8;13)(p11;q12) myeloproliferative syndrome.
Blood 1998;92(5):1735-42.
1998: Myrtle Y Gordon; Stephen B Marley; John L Lewis; R John Davidson; DX Nguyen; Francis H Grand; T A Amos; John M Goldman
Treatment with interferon-alpha preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM.
The Journal of clinical investigation 1998;102(4):710-5.
1998: Francesco Dazzi; D Capelli; Robert P Hasserjian; Finbarr E Cotter; M Corbo; A Poletti; W Chinswangwatanakul; John M Goldman; Myrtle Y Gordon
The kinetics and extent of engraftment of chronic myelogenous leukemia cells in non-obese diabetic/severe combined immunodeficiency mice reflect the phase of the donor's disease: an in vivo model of chronic myelogenous leukemia biology.
Blood 1998;92(4):1390-6.
1998: Michael W N Deininger; John M Goldman
Chronic myeloid leukemia.
Current opinion in hematology 1998;5(4):302-8.
1998: F van Rhee; D Savage; J Blackwell; K Orchard; Francesco Dazzi; F Lin; Andrew Chase; J Bungey; Nicholas C P Cross; Jane Apperley; Richard Szydlo; John M Goldman
Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
Bone marrow transplantation 1998;21(10):1055-61.
1998: M Carapeti; Ricardo Aguiar; John M Goldman; Nicholas C P Cross
A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Blood 1998;91(9):3127-33.
1998: Stephen B Marley; John L Lewis; John M Goldman; Myrtle Y Gordon
Discordant erythropoiesis in CML.
Leukemia 1998;12(3):444-5.
1998: S Coulthard; Andrew Chase; K Orchard; Ann Watmore; A Vora; John M Goldman; David M Swirsky
Two cases of inv(8)(p11q13) in AML with erythrophagocytosis: a new cytogenetic variant.
British journal of haematology 1998;100(3):561-3.
1998: J O'Donnell; John M Goldman; K Wagner; G Ehinger; N Martin; M Leahy; N Kariuki; Inderjeet Dokal; I Roberts
Donor-derived Plasmodium vivax infection following volunteer unrelated bone marrow transplantation.
Bone marrow transplantation 1998;21(3):313-4.
1998: Michael W N Deininger; S Bose; J Gora-Tybor; X H Yan; John M Goldman; Junia V Melo
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation.
Cancer research 1998;58(3):421-5.
1998: F Dazzi; John M Goldman
Adoptive immunotherapy following allogeneic bone marrow transplantation.
Annual review of medicine 1998;49():329-40.
1998: John L Lewis; Stephen B Marley; N M Blackett; Richard Szydlo; John M Goldman; Myrtle Y Gordon
Interleukin 3 (IL-3), but not stem cell factor (SCF) increases self-renewal by human erythroid burst-forming units (BFU-E) in vitro.
Cytokine 1998;10(1):49-54.
1998: John M Goldman; Norbert Schmitz; D Niethammer; A Gratwohl
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation.
Bone marrow transplantation 1998;21(1):1-7.
1997: Pia Raanani; Francesco Dazzi; J Sohal; Richard Szydlo; F van Rhee; A Reiter; F Lin; John M Goldman; Nicholas C P Cross
The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation.
British journal of haematology 1997;99(4):945-50.
1997: Ricardo Aguiar; Andrew Chase; David Oscier; M Carapeti; John M Goldman; Nicholas C P Cross
Characterization of a t(10;12)(q24;p13) in a case of CML in transformation.
Genes, chromosomes & cancer 1997;20(4):408-11.
1997: Michael W N Deininger; John M Goldman; N Lydon; Junia V Melo
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Blood 1997;90(9):3691-8.
1997: Ricardo Aguiar; Andrew Chase; S Coulthard; DH Macdonald; M Carapeti; A Reiter; J Sohal; A Lennard; John M Goldman; Nicholas C P Cross
Abnormalities of chromosome band 8p11 in leukemia: two clinical syndromes can be distinguished on the basis of MOZ involvement.
Blood 1997;90(8):3130-5.
1997: F van Rhee; R M Szydlo; J Hermans; A Devergie; F Frassoni; W Arcese; T de Witte; H J Kolb; D Niederwiser; N Jacobsen; G Gahrton; G Bandini; E Carreras; A Bacigalupo; M Michallet; T Ruutu; J Reiffers; John M Goldman; Jane Apperley; A Gratwohl
Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Bone marrow transplantation 1997;20(7):553-60.
1997: T E Hawkins; Stephen B Marley; S G O'Brien; Myrtle Y Gordon; John M Goldman
CD34+ cell selection in chronic phase chronic myeloid leukaemia: a comparison of laboratory grade columns.
Bone marrow transplantation 1997;20(5):409-13.
1997: John M Goldman
Chronic myeloid leukemia.
Current opinion in hematology 1997;4(4):277-85.
1997: M Carapeti; AA Soede-Bobok; A Hochhaus; Heinz Sill; Ivo P Touw; John M Goldman; Nicholas C P Cross
Rarity of dominant-negative mutations of the G-CSF receptor in patients with blast crisis of chronic myeloid leukemia or de novo acute leukemia.
Leukemia 1997;11(7):1005-8.
1997: A Hochhaus; X H Yan; A Willer; R Hehlmann; Myrtle Y Gordon; John M Goldman; Junia V Melo
Expression of interferon regulatory factor (IRF) genes and response to interferon-alpha in chronic myeloid leukaemia.
Leukemia 1997;11(7):933-9.
1997: M Carapeti; John M Goldman; Nicholas C P Cross
Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia.
European journal of haematology 1997;58(5):346-9.
1997: Myrtle Y Gordon; John L Lewis; Stephen B Marley; Francis H Grand; John M Goldman
Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinositol-anchored cell adhesion/signalling mechanism.
British journal of haematology 1997;96(3):647-53.
1997: Ricardo Aguiar; Heinz Sill; John M Goldman; Nicholas C P Cross
The commonly deleted region at 9p21-22 in lymphoblastic leukemias spans at least 400 kb and includes p16 but not p15 or the IFN gene cluster.
Leukemia 1997;11(2):233-8.
1996: Ricardo Aguiar; J Sohal; F van Rhee; M Carapeti; I M Franklin; A H Goldstone; John M Goldman; Nicholas C P Cross
TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party.
British journal of haematology 1996;95(4):673-7.
1996: F Lin; M A Kirkland; F V van Rhee; Andrew Chase; S Coulthard; J Bungey; John M Goldman; Nicholas C P Cross
Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1996;18(6):1147-52.
1996: S B Marley; John L Lewis; M A Scott; John M Goldman; Myrtle Y Gordon
Evaluation of "discordant maturation' in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM).
British journal of haematology 1996;95(2):299-305.
1996: J R Seale; S Varma; D M Swirsky; Pier Paolo Pandolfi; John M Goldman; Nicholas C P Cross
Quantification of PML-RAR alpha transcripts in acute promyelocytic leukaemia: explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by alpha interferon.
British journal of haematology 1996;95(1):95-101.
1996: Myrtle Y Gordon; John M Goldman
Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment.
British journal of haematology 1996;95(1):10-20.
1996: Ricardo Aguiar; Heinz Sill; Andreas Hochhaus; John M Goldman; Nicholas C P Cross
Molecular investigation of secondary chronic myeloid leukemia.
Blood 1996;88(7):2808-9.
1996: Andreas Hochhaus; A Reiter; Heyko Skladny; Junia V Melo; C Sick; Ute Berger; J Q Guo; R B Arlinghaus; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
Blood 1996;88(6):2236-40.
1996: S A Rule; David G Savage; S G O'Brien; K Orchard; C McDonald; J Davidson; F Matthey; J T Reilly; G Bardhan; E Miller; T Cranfield; J F Apperley; John M Goldman
Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia.
British journal of haematology 1996;94(4):694-8.
1996: A Spencer; X H Yan; Andrew Chase; John M Goldman; Junia V Melo
BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions.
British journal of haematology 1996;94(4):654-8.
1996: M Carapeti; John M Goldman; Nicholas C P Cross
Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia.
Leukemia 1996;10(9):1561.
1996: H R Jäger; E J Williams; David G Savage; S A Rule; Joseph V Hajnal; K Sikora; John M Goldman; Graeme M Bydder
Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia.
AJNR. American journal of neuroradiology 1996;17(7):1275-82.
1996: Myrtle Y Gordon; John L Lewis; Francis H Grand; Stephen B Marley; John M Goldman
Phenotype and progeny of primitive adherent human hematopoietic progenitors.
Leukemia 1996;10(8):1347-53.
1996: Ricardo Aguiar; Patricia Dahia; Heinz Sill; sergio toledo; John M Goldman; Nicholas C P Cross
Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas.
Clinical endocrinology 1996;45(1):93-6.
1996: Heinz Sill; John M Goldman; Nicholas C P Cross
Rarity of microsatellite alterations in acute myeloid leukaemia.
British journal of cancer 1996;74(2):255-7.
1996: Junia V Melo; X H Yan; J Diamond; F Lin; Nicholas C P Cross; John M Goldman
Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.
Leukemia 1996;10(7):1217-21.
1996: F Al-Jehani; Andreas Hochhaus; A Spencer; John M Goldman; Junia V Melo
Expression of the LH2 gene in chronic myeloid leukaemia cells.
Leukemia 1996;10(7):1122-6.
1996: F van Rhee; Andreas Hochhaus; F Lin; Junia V Melo; John M Goldman; Nicholas C P Cross
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
Blood 1996;87(12):5213-7.
1996: Stephen B Marley; John L Lewis; John M Goldman; Myrtle Y Gordon
Abnormal kinetics of colony formation by erythroid burst-forming units (BFU-E) in chronic myeloid leukaemia.
British journal of haematology 1996;93(4):878-83.
1996: F Lin; F van Rhee; John M Goldman; Nicholas C P Cross
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Blood 1996;87(10):4473-8.
1996: John M Goldman
Autografting for CML--overview and perspectives.
Bone marrow transplantation 1996;17 Suppl 3():S71-4.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
Bone marrow transplantation 1996;17 Suppl 3():S41-4.
1996: E Lutz; K N Ward; Richard Szydlo; John M Goldman
Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
Journal of medical virology 1996;49(1):61-5.
1996: J G Zhang; F Lin; Andrew Chase; John M Goldman; Nicholas C P Cross
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Blood 1996;87(6):2588-93.
1996: Heinz Sill; S A Rule; D J Joske; Andrew Chase; F Lin; John M Goldman; Nicholas C P Cross
Reconstitution with Philadelphia chromosome-negative recipient haematopoiesis early after allogeneic BMT for CML.
Bone marrow transplantation 1996;17(3):453-5.
1996: Junia V Melo; Andreas Hochhaus; X H Yan; John M Goldman
Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia.
British journal of haematology 1996;92(3):684-6.
1996: Heinz Sill; Ricardo Aguiar; H Schmidt; Andreas Hochhaus; John M Goldman; Nicholas C P Cross
Mutational analysis of the p15 and p16 genes in acute leukaemias.
British journal of haematology 1996;92(3):681-3.
1996: M J Clemons; Y F Williams; John M Goldman; A J Barrett
Long-term control of polycythemia rubra vera with recombinant alpha interferon.
Hematological oncology 1996;14(1):37-40.
1996: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; Philip J Mason; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
Blood 1996;87(4):1549-55.
1996: T I Mughal; John M Goldman
An integrated approach to the management of chronic myeloid leukemia.
Annals of Saudi medicine 1996;16(1):1-2.
1995: A Spencer; T Vulliamy; Andrew Chase; John M Goldman
Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia.
Leukemia 1995;9(12):2138-9.
1995: A Spencer; Richard Szydlo; Paul A Brookes; E Kaminski; S Rule; F van Rhee; K N Ward; G Hale; H Waldmann; Jill M Hows; J R Batchelor; John M Goldman
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient.
Blood 1995;86(9):3590-7.
1995: T A Amos; John L Lewis; Francis H Grand; R P Gooding; John M Goldman; Myrtle Y Gordon
Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, X-irradiation and glucocorticoids.
British journal of haematology 1995;91(2):387-93.
1995: D Macdonald; Ricardo Aguiar; Philip J Mason; John M Goldman; Nicholas C P Cross
A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.
Leukemia 1995;9(10):1628-30.
1995: A Spencer; S G O'Brien; John M Goldman
Options for therapy in chronic myeloid leukaemia.
British journal of haematology 1995;91(1):2-7.
1995: Andreas Hochhaus; F Lin; A Reiter; Heyko Skladny; F van Rhee; P C Shepherd; N C Allan; Rüdiger Hehlmann; John M Goldman; Nicholas C P Cross
Variable numbers of BCR-ABL transcripts persist in CML patients who achieve complete cytogenetic remission with interferon-alpha.
British journal of haematology 1995;91(1):126-31.
1995: Myrtle Y Gordon; John L Lewis; M A Scott; I A Roberts; John M Goldman
Probability of progenitor renewal (PPR) and production of clonogenic progeny (CFU-GM) by primitive adherent progenitor cells in adult human bone marrow and umbilical cord blood.
British journal of haematology 1995;90(4):744-9.
1995: Junia V Melo; John M Goldman
Reply to Haas: Are ABL and BCR imprinted? (Leukemia 1995; 9: 740-743).
Leukemia 1995;9(8):1407-8.
1995: Myrtle Y Gordon; N M Blackett; John L Lewis; John M Goldman
Evidence for a mechanism that can provide both short-term and long-term haemopoietic repopulation by a seemingly uniform population of primitive human haemopoietic precursor cells.
Leukemia 1995;9(7):1252-6.
1995: F Lin; Andrew Chase; J Bungey; John M Goldman; Nicholas C P Cross
Correlation between the proportion of Philadelphia chromosome-positive metaphase cells and levels of BCR-ABL mRNA in chronic myeloid leukaemia.
Genes, chromosomes & cancer 1995;13(2):110-4.
1995: A Spencer; Paul A Brookes; E Kaminski; Jill M Hows; Richard Szydlo; F van Rhee; John M Goldman; J R Batchelor
Cytotoxic T lymphocyte precursor frequency analyses in bone marrow transplantation with volunteer unrelated donors. Value in donor selection.
Transplantation 1995;59(9):1302-8.
1995: Francesco Lanza; S Bi; Sabrina Moretti; G Castoldi; John M Goldman
Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides.
British journal of haematology 1995;90(1):8-14.
1995: F van Rhee; A Kasprzyk; A Jamil; H Dickinson; F Lin; Nicholas C P Cross; M C Galvin; John M Goldman; Lorna M Secker-Walker
Detection of the BCR-ABL gene by reverse transcription/polymerase chain reaction and fluorescence in situ hybridization in a patient with Philadelphia chromosome negative acute lymphoblastic leukaemia.
British journal of haematology 1995;90(1):225-8.
1995: J G Zhang; John M Goldman; Nicholas C P Cross
Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR.
British journal of haematology 1995;90(1):138-46.
1995: J Diamond; John M Goldman; Junia V Melo
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
Blood 1995;85(8):2171-5.
1995: Heinz Sill; John M Goldman; Nicholas C P Cross
Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia.
Blood 1995;85(8):2013-6.
1995: Junia V Melo; X H Yan; J Diamond; John M Goldman
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Leukemia 1995;9(4):734-9.
1995: F van Rhee; D I Marks; F Lin; Richard Szydlo; Andreas Hochhaus; J Treleaven; C Delord; Nicholas C P Cross; John M Goldman
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow.
Leukemia 1995;9(2):329-35.
1994: Anthony P Schwarer; YZ Jiang; S Deacock; Paul A Brookes; A J Barrett; John M Goldman; J R Batchelor; Robert I Lechler
Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation.
Transplantation 1994;58(11):1198-203.
1994: Junia V Melo; N S Kent; X H Yan; John M Goldman
Controls for reverse transcriptase-polymerase chain reaction amplification of BCR-ABL transcripts.
Blood 1994;84(11):3984-6.
1994: Junia V Melo; X H Yan; J Diamond; John M Goldman
Lack of imprinting of the ABL gene.
Nature genetics 1994;8(4):318-9.
1994: S G O'Brien; M A Kirkland; Junia V Melo; M H Rao; R J Davidson; C McDonald; John M Goldman
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Leukemia 1994;8(12):2156-62.
1994: H Silly; Andrew Chase; Ken Mills; U Apfelbeck; S Sormann; John M Goldman; Nicholas C P Cross
No evidence for microsatellite instability or consistent loss of heterozygosity at selected loci in chronic myeloid leukaemia blast crisis.
Leukemia 1994;8(11):1923-8.
1994: F van Rhee; F Lin; Nicholas C P Cross; C D Reid; A K Lakhani; Richard Szydlo; John M Goldman
Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia.
Bone marrow transplantation 1994;14(4):609-12.
1994: B Garicochea; F van Rhee; A Spencer; Andrew Chase; F Lin; Nicholas C P Cross; John M Goldman
Aplasia after donor lymphocyte infusion (DLI) for CML in relapse after sex-mismatched BMT: recovery of donor-type haemopoiesis predicted by non-isotopic in situ hybridization (ISH).
British journal of haematology 1994;88(2):400-2.
1994: C Hoyle; John M Goldman
Life-threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams.
Bone marrow transplantation 1994;14(2):247-52.
1994: B Garicochea; Andrew Chase; A Lazaridou; John M Goldman
T lymphocytes in chronic myelogenous leukaemia (CML): no evidence of the BCR/ABL fusion gene detected by fluorescence in situ hybridization in 14 patients.
Leukemia 1994;8(7):1197-201.
1994: M A Kirkland; S G O'Brien; John M Goldman
Antisense therapeutics in haematological malignancies.
British journal of haematology 1994;87(3):447-52.
1994: D G Savage; John M Goldman
Approaches to the treatment of chronic myeloid leukemia.
International journal of hematology 1994;60(1):1-21.
1994: F van Rhee; F Lin; J O Cullis; A Spencer; Nicholas C P Cross; Andrew Chase; B Garicochea; J Bungey; J Barrett; John M Goldman
Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematologic relapse.
Blood 1994;83(11):3377-83.
1994: D Macdonald; S M Sheerin; Nicholas C P Cross; A Spencer; John M Goldman
An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case.
British journal of haematology 1994;86(4):879-80.
1994: John M Goldman
Management of chronic myeloid leukaemia.
Blood reviews 1994;8(1):21-9.
1994: F Lin; John M Goldman; Nicholas C P Cross
A comparison of the sensitivity of blood and bone marrow for the detection of minimal residual disease in chronic myeloid leukaemia.
British journal of haematology 1994;86(3):683-5.
1994: P S Ramrakha; D I Marks; S G O'Brien; M Yacoub; J B Schofield; John M Goldman
Orthotopic cardiac transplantation for dilated cardiomyopathy after allogeneic bone marrow transplantation.
Clinical transplantation 1994;8(1):23-6.
1994: S Bi; F Lanza; John M Goldman
The involvement of "tumor suppressor" p53 in normal and chronic myelogenous leukemia hemopoiesis.
Cancer research 1994;54(2):582-6.
1994: Junia V Melo; Han Myint; D A Galton; John M Goldman
P190BCR-ABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?
Leukemia 1994;8(1):208-11.
1994: Nicholas C P Cross; Junia V Melo; L Feng; John M Goldman
An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders.
Leukemia 1994;8(1):186-9.
1994: J O Cullis; A J Barrett; John M Goldman; R I Lechler
Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines.
Leukemia 1994;8(1):165-70.
1994: S Bi; C M Barton; Nick Lemoine; Nicholas C P Cross; John M Goldman
Retroviral transduction of Philadelphia-positive chronic myeloid leukemia cells with a human mutant p53 cDNA and its effect on in vitro proliferation.
Experimental hematology 1994;22(1):95-9.
1994: John M Goldman
Autografting for CML--where does it fit in to the overall treatment strategy?
Bone marrow transplantation 1994;14 Suppl 3():S74-7.
1994: S G O'Brien; M A Kirkland; John M Goldman
European School of Oncology Task Force Papers: gene therapy--a future in cancer management? Antisense therapy for malignant disease.
European journal of cancer (Oxford, England : 1990) 1994;30A(8):1160-4.
1993: S Bi; F Lanza; John M Goldman
The abnormal p53 proteins expressed in CML cell lines are non-functional.
Leukemia 1993;7(11):1840-5.
1993: T Mughal; C Hoyle; John M Goldman
Autografting for patients with chronic myeloid leukemia--the Hammersmith experience.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():20-2.
1993: J Barrett; A Guimaraes; J Cullis; John M Goldman
Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
Stem cells (Dayton, Ohio) 1993;11 Suppl 3():104-8.
1993: Francesco Lanza; S Bi; G Castoldi; John M Goldman
Abnormal expression of N-CAM (CD56) adhesion molecule on myeloid and progenitor cells from chronic myeloid leukemia.
Leukemia 1993;7(10):1570-5.
1993: Nicholas C P Cross; L Feng; Andrew Chase; J Bungey; T P Hughes; John M Goldman
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Blood 1993;82(6):1929-36.
1993: M A Kirkland; S G O'Brien; C McDonald; R J Davidson; Nicholas C P Cross; John M Goldman
BCR-ABL antisense purging in chronic myeloid leukaemia.
Lancet 1993;342(8871):614.
1993: P De Fabritiis; charles dowding; J Bungey; Andrew Chase; G Angus; Richard Szydlo; John M Goldman
Phenotypic characterization of normal and CML CD34-positive cells: only the most primitive CML progenitors include Ph-neg cells.
Leukemia & lymphoma 1993;11(1-2):51-61.
1993: D I Marks; J O Cullis; K N Ward; S Lacey; R Syzdlo; T P Hughes; Anthony P Schwarer; E Lutz; A J Barrett; Jill M Hows; J R Batchelor; John M Goldman
Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors. A comparison of complications in the first 2 years.
Annals of internal medicine 1993;119(3):207-14.
1993: Junia V Melo; D E Gordon; A Tuszynski; S Dhut; Bryan D Young; John M Goldman
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Blood 1993;81(10):2488-91.
1993: C Hoyle; John M Goldman
Pyomyositis in a patient with myeloma responding to antibiotics alone.
Journal of internal medicine 1993;233(5):419-21.
1993: A C Nathwani; John M Goldman
Management of chronic myeloid leukaemia in lymphoid blast transformation.
Haematologica 1993;78(3):162-6.
1993: Nicholas C P Cross; T P Hughes; L Feng; P O'Shea; J Bungey; D I Marks; A Ferrant; P Martiat; John M Goldman
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse.
British journal of haematology 1993;84(1):67-74.
1993: J R Batchelor; Anthony P Schwarer; Z J Yin; A J Barrett; John M Goldman; Robert I Lechler
Helper T-lymphocyte precursor frequencies predict risks of graft-versus-host disease in bone marrow transplantation.
Transplantation proceedings 1993;25(1 Pt 2):1237-8.
1993: YZ Jiang; J O Cullis; Edward Kanfer; John M Goldman; A J Barrett
T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1993;11(2):133-8.
1993: Anthony P Schwarer; YZ Jiang; Paul A Brookes; A J Barrett; J R Batchelor; John M Goldman; Robert I Lechler
Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation.
Lancet 1993;341(8839):203-5.
1993: Junia V Melo; D E Gordon; Nicholas C P Cross; John M Goldman
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
Blood 1993;81(1):158-65.
1993: John M Goldman
Chronic myeloid leukaemia--the XXI century.
Leukemia & lymphoma 1993;11 Suppl 1():7-9.
1993: Nicholas C P Cross; L Feng; J Bungey; John M Goldman
Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction.
Leukemia & lymphoma 1993;11 Suppl 1():39-43.
1992: A P Schwarer; J M Hughes; B Trotman-Dickenson; T Krausz; John M Goldman
A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation.
Transplantation 1992;54(6):1002-8.
1992: D I Marks; B Dousset; A Robson; G Imvrios; J A Buckels; E Elias; J M Neuberger; C Foster; R Batchelor; John M Goldman
Orthotopic liver transplantation for hepatic GVHD following allogeneic BMT for chronic myeloid leukaemia.
Bone marrow transplantation 1992;10(5):463-6.
1992: S Bi; T Hughes; J Bungey; Andrew Chase; P de Fabritiis; John M Goldman
p53 in chronic myeloid leukemia cell lines.
Leukemia 1992;6(8):839-42.
1992: Junia V Melo; John M Goldman
Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.
Leukemia 1992;6(8):786-90.
1992: J O Cullis; D I Marks; Anthony P Schwarer; A J Barrett; Jill M Hows; D M Swirsky; John M Goldman
Relapse into blast crisis following bone marrow transplantation for chronic phase chronic myeloid leukaemia: a report of five cases.
British journal of haematology 1992;81(3):378-82.
1992: E R Kaminski; Jill M Hows; John M Goldman; J R Batchelor
Lymphocytes from multi-transfused patients exhibit cytotoxicity against autologous cells.
British journal of haematology 1992;81(1):23-6.
1992: S J Deacock; Anthony P Schwarer; J Bridge; J R Batchelor; John M Goldman; Robert I Lechler
Evidence that umbilical cord blood contains a higher frequency of HLA class II-specific alloreactive T cells than adult peripheral blood. A limiting dilution analysis.
Transplantation 1992;53(5):1128-34.
1992: John M Goldman
Bone marrow transplantation for chronic myelogenous leukemia.
Current opinion in oncology 1992;4(2):259-63.
1992: J O Cullis; YZ Jiang; Anthony P Schwarer; T P Hughes; A J Barrett; John M Goldman
Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation.
Blood 1992;79(5):1379-81.
1992: John M Goldman
Bone marrow transplantation for chronic myeloid leukaemia.
Leukemia 1992;6 Suppl 2():22-3.
1992: J O Cullis; Anthony P Schwarer; T P Hughes; Jill M Hows; I Franklin; G Morgenstern; John M Goldman
Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning.
British journal of haematology 1992;80(1):33-9.
1991: YZ Jiang; Edward Kanfer; D Macdonald; J O Cullis; John M Goldman; A J Barrett
Graft-versus-leukaemia following allogeneic bone marrow transplantation: emergence of cytotoxic T lymphocytes reacting to host leukaemia cells.
Bone marrow transplantation 1991;8(4):253-8.
1991: R Weide; charles dowding; B Sucai; J Bungey; Andrew Chase; John M Goldman
Inactivation of the retinoblastoma susceptibility gene in a human high grade non-Hodgkin's lymphoma cell line.
British journal of haematology 1991;78(4):500-5.
1991: Myrtle Y Gordon; J Atkinson; D Clarke; charles dowding; John M Goldman; P G Grimsley; M Siczkowski; Mel F Greaves
Deficiency of a phosphatidylinositol-anchored cell adhesion molecule influences haemopoietic progenitor binding to marrow stroma in chronic myeloid leukaemia.
Leukemia 1991;5(8):693-8.
1991: E R Kaminski; Jill M Hows; J Bridge; N J Davey; Paul A Brookes; J E Green; John M Goldman; J R Batchelor
Cytotoxic T lymphocyte precursor (CTL-p) frequency analysis in unrelated donor bone marrow transplantation: two case studies.
Bone marrow transplantation 1991;8(1):47-50.
1991: A Bashey; T Vulliamy; B S Cai; Anthony P Schwarer; John M Goldman
Non-lymphoid blast crisis of CML with rearrangement of immunoglobulin and T-cell receptor delta genes.
European journal of haematology 1991;47(1):36-41.
1991: J Osterholz; charles dowding; A P Guo; M Siczkowski; John M Goldman
Interferon-alpha alters the distribution of CFU-GM between the adherent and nonadherent compartments in long-term cultures of chronic myeloid leukemia marrow.
Experimental hematology 1991;19(5):326-31.
1991: T P Hughes; G J Morgan; P Martiat; John M Goldman
Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.
Blood 1991;77(4):874-8.
1991: charles dowding; A P Guo; D Maisin; Myrtle Y Gordon; John M Goldman
The effects of interferon-alpha on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint.
British journal of haematology 1991;77(2):165-71.
1991: John M Goldman; T Hughes
Detection and significance of minimal residual disease in patients with leukaemia and lymphoma.
Bone marrow transplantation 1991;7 Suppl 1():66-9.
1991: S Mackinnon; J Bungey; Andrew Chase; W Paulsen; Jill M Hows; John M Goldman
Origin and function of adherent lymphokine activated killer cells in patients with chronic myeloid leukaemia who relapse following bone marrow transplantation.
British journal of haematology 1991;77(1):60-5.
1991: John M Goldman
Bone marrow transplantation for chronic myeloid leukaemia.
Bone marrow transplantation 1991;7 Suppl 2():62-3.
1991: T P Hughes; P O'Shea; G Morgan; P Martiat; John M Goldman
Persistence of BCR/ABL transcripts after BMT for CML detected by PCR reflects a high risk of relapse.
Bone marrow transplantation 1991;7 Suppl 2():23.
1990: S Mackinnon; Jill M Hows; John M Goldman
Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia.
Blood 1990;76(10):2037-45.
1990: E R Kaminski; Jill M Hows; John M Goldman; J R Batchelor
Pretransfused patients with severe aplastic anaemia exhibit high numbers of cytotoxic T lymphocyte precursors probably directed at non-HLA antigens.
British journal of haematology 1990;76(3):401-5.
1990: A Hernandez; J Osterholz; C M Price; LM Wiedemann; Myrtle Y Gordon; John M Goldman; G J Morgan
Detection of the hybrid BCR/ABL messenger RNA in single CFU-GM colonies using the polymerase chain reaction.
Experimental hematology 1990;18(10):1142-4.
1990: S Mackinnon; Jill M Hows; John M Goldman; Chris Arthur; T Hughes; J F Apperley; L Jones; J R Batchelor; Paul A Brookes; D Catovsky
Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors.
Experimental hematology 1990;18(5):421-5.
1990: J R Batchelor; E Kaminski; Giovanna Lombardi; John M Goldman; Robert I Lechler
Individual variation in alloresponsiveness and the molecular basis of allorecognition.
Human immunology 1990;28(2):96-103.
1990: S Mackinnon; Jill M Hows; John M Goldman
Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia.
Leukemia 1990;4(4):287-91.
1990: John M Goldman; G Grosveld; David Baltimore; R P Gale
Chronic myelogenous leukemia--the unfolding saga.
Leukemia 1990;4(3):163-7.
1990: John M Goldman
Molecular biology and treatment of chronic myelogenous leukemia.
Current opinion in oncology 1990;2(1):49-54.
1990: T P Hughes; John M Goldman
Biological importance of residual leukaemic cells after BMT for CML: does the polymerase chain reaction help?
Bone marrow transplantation 1990;5(1):3-6.
1990: J Jaubert; P Martiat; charles dowding; N Ifrah; John M Goldman
The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia.
British journal of haematology 1990;74(1):30-5.
1989: John M Goldman; S Mackinnon
Bone marrow transplantation for chronic myeloid leukaemia using matched unrelated donors.
Bone marrow transplantation 1989;4 Suppl 4():38-9.
1989: T P Hughes; K Economou; S Mackinnon; M Vlitos; Chris Arthur; A P Guo; Feyruz V Rassool; J F Apperley; J Hows; John M Goldman
Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow.
British journal of haematology 1989;73(4):462-7.
1989: E Kaminski; J Hows; S Man; Paul A Brookes; S Mackinnon; T Hughes; O Avakian; John M Goldman; J R Batchelor
Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation.
Transplantation 1989;48(4):608-13.
1989: P Martiat; N Ifrah; Feyruz V Rassool; G Morgan; Francis Giles; J Gow; John M Goldman
Molecular analysis of Philadelphia positive essential thrombocythemia.
Leukemia 1989;3(8):563-5.
1989: S J Bowcock; D A Galton; John M Goldman
Marrow aplasia developing 3 years after treatment with busulphan for chronic myeloid leukaemia.
European journal of haematology 1989;42(5):496-7.
1989: G J Morgan; T Hughes; J W Janssen; J Gow; A P Guo; John M Goldman; LM Wiedemann; C R Bartram
Polymerase chain reaction for detection of residual leukaemia.
Lancet 1989;1(8644):928-9.
1989: Nicholas James; J F Apperley; K C Kam; S MacKinnon; John M Goldman; A W Goolden; K Sikora
Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia.
Clinical radiology 1989;40(2):195-8.
1989: John M Goldman
Allogeneic bone marrow transplantation: state of the art and future directions.
Bone marrow transplantation 1989;4 Suppl 1():133-4.
1989: Inderjeet Dokal; L Jones; M Deenmamode; S M Lewis; John M Goldman
Allogeneic bone marrow transplantation for primary myelofibrosis.
British journal of haematology 1989;71(1):158-60.
1989: J F Apperley; charles dowding; J Hibbin; J Buiter; E Matutes; P J Sissons; M Gordon; John M Goldman
The effect of cytomegalovirus on hemopoiesis: in vitro evidence for selective infection of marrow stromal cells.
Experimental hematology 1989;17(1):38-45.
1989: John M Goldman
Recent advances in molecular biology of chronic myeloid leukaemia: is the pathogenetic puzzle approaching solution?
Bone marrow transplantation 1989;4 Suppl 1():129-30.
1988: C M Price; Feyruz V Rassool; M K Shivji; J Gow; C J Tew; C Haworth; John M Goldman; LM Wiedemann
Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.
Blood 1988;72(5):1829-32.
1988: Jeffrey N Weitzel; Jill M Hows; A J Jeffreys; G L Min; John M Goldman
Use of a hypervariable minisatellite DNA probe (33.15) for evaluating engraftment two or more years after bone marrow transplantation for aplastic anaemia.
British journal of haematology 1988;70(1):91-7.
1988: H Koeppler; John M Goldman
'Auto'-immune neutropenia after allogeneic bone marrow transplantation unresponsive to conventional immunosuppression but resolving promptly after splenectomy.
European journal of haematology 1988;41(2):182-5.
1988: J F Apperley; John M Goldman
Cytomegalovirus: biology, clinical features and methods for diagnosis.
Bone marrow transplantation 1988;3(4):253-64.
1988: J F Apperley; F R Mauro; John M Goldman; W Gregory; Chris Arthur; J Hows; W Arcese; G Papa; F Mandelli; D Wardle
Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect.
British journal of haematology 1988;69(2):239-45.
1988: Chris Arthur; J F Apperley; A P Guo; Feyruz V Rassool; L M Gao; John M Goldman
Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase.
Blood 1988;71(5):1179-86.
1988: P S Ganly; C Arthur; John M Goldman; W E Schulenburg
Foscarnet as treatment for cytomegalovirus retinitis following bone marrow transplantation.
Postgraduate medical journal 1988;64(751):389-91.
1988: charles dowding; Myrtle Y Gordon; John M Goldman
Increased DR antigen expression by committed hemopoietic progenitor cells but not primitive progenitor cells in chronic myeloid leukemia.
Experimental hematology 1988;16(3):171-5.
1988: S Mackinnon; John M Goldman
Bone marrow transplantation for patients with chronic myeloid leukaemia.
British journal of hospital medicine 1988;39(3):226-30.
1987: John M Goldman
Bone marrow transplantation for chronic myeloid leukaemia.
Hematological oncology 1987;5(4):265-79.
1987: John M Goldman
Prospects for cure in leukaemia.
Journal of clinical pathology 1987;40(9):985-94.
1987: L Jones; S L Thein; A J Jeffreys; J F Apperley; D Catovsky; John M Goldman
Identical twin marrow transplantation for 5 patients with chronic myeloid leukaemia: role of DNA finger-printing to confirm monozygosity in 3 cases.
European journal of haematology 1987;39(2):144-7.
1987: L Jones; J Ball; J F Apperley; L Ginsberg; John M Goldman
Subacute thyroiditis after bone marrow transplant for chronic granulocytic leukaemia.
Bone marrow transplantation 1987;1(4):411-2.
1987: Trivadi Ganesan; Feyruz V Rassool; A P Guo; B D Young; D A Galton; John M Goldman
Rearrangement of the bcr gene in Philadelphia-chromosome-negative chronic myeloid leukemia.
Haematology and blood transfusion 1987;31():153-9.
1987: F Brito-Babapulle; J F Apperley; Feyruz V Rassool; A P Guo; charles dowding; John M Goldman
Complete remission after autografting for chronic myeloid leukaemia.
Leukemia research 1987;11(12):1115-7.
1986: T Robak; charles dowding; G Garewal; J A Hibbin; K H Th'ng; John M Goldman
Antigenic determinants on myeloid leukaemia colony-forming cells resemble those of normal myeloid progenitor cells and differ from those of circulating blast cells.
British journal of haematology 1986;64(1):133-48.
1986: H Martin; J A Hibbin; charles dowding; E Matutes; R Tindle; John M Goldman
Purification of haemopoietic progenitor cells from patients with chronic granulocytic leukaemia using percoll density gradients and elutriation.
British journal of haematology 1986;63(1):187-98.
1985: Myrtle Y Gordon; J A Hibbin; charles dowding; E C Gordon-Smith; John M Goldman
Separation of human blast progenitors from granulocytic, erythroid, megakaryocytic, and mixed colony-forming cells by "panning" on cultured marrow-derived stromal layers.
Experimental hematology 1985;13(9):937-40.
1984: M E Haines; John M Goldman; A M Worsley; D M McCarthy; S E Wyatt; charles dowding; L Kearney; K H Th'ng; N J Wareham; A Pollock
Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival for some patients.
British journal of haematology 1984;58(4):711-21.
1984: charles dowding; K H Th'ng; John M Goldman; D A Galton
Increased T-lymphocyte numbers in chronic granulocytic leukemia before treatment.
Experimental hematology 1984;12(10):811-15.
1984: A S Baughan; A M Worsley; D M McCarthy; Jill M Hows; D Catovsky; E C Gordon-Smith; D A Galton; John M Goldman
Haematological reconstitution and severity of graft-versus-host disease after bone marrow transplantation for chronic granulocytic leukaemia: the influence of previous splenectomy.
British journal of haematology 1984;56(3):445-54.
1983: A W Goolden; John M Goldman; K C Kam; P A Dunn; A S Baughan; D M McCarthy; A M Worsley; E C Gordon-Smith; D Samson; D Catovsky; D A Galton
Fractionation of whole body irradiation before bone marrow transplantation for patients with leukaemia.
The British journal of radiology 1983;56(664):245-50.
1983: A B Mehta; A S Baughan; D Catovsky; John M Goldman; S A Johnson; D A Galton
Reversal of marrow fibrosis in acute megakaryoblastic leukaemia after remission-induction and consolidation chemotherapy followed by bone marrow transplantation.
British journal of haematology 1983;53(3):445-9.
1982: John M Goldman; J Hibbin; L Kearney; K Orchard; K H Th'ng
HLA-DR monoclonal antibodies inhibit the proliferation of normal and chronic granulocytic leukaemia myeloid progenitor cells.
British journal of haematology 1982;52(3):411-20.
1982: John M Goldman; A S Baughan; D M McCarthy; A M Worsley; Jill M Hows; E C Gordon-Smith; D Catovsky; J R Batchelor; A W Goolden; D A Galton
Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia.
Lancet 1982;2(8299):623-5.
1982: L Kearney; K H Orchard; J Hibbin; John M Goldman
T-cell cytogenetics in chronic granulocytic leukaemia.
Lancet 1982;1(8276):858.
1981: John M Goldman; D Catovsky; A W Goolden; S A Johnson; D A Galton
Buffy coat autografts for patients with chronic granulocytic leukaemia in transformation.
Blut 1981;42(3):149-55.
1981: John M Goldman; S A Johnson; D Catovsky; G Agnarsdottir; A W Goolden; D A Galton
Identical twin marrow transplantation for patients with leukemia and lymphoma.
Transplantation 1981;31(2):140-1.
1980: John M Goldman; F Shiota; K H Th'ng; K H Orchard
Circulating granulocytic and erythroid progenitor cells in chronic granulocytic leukaemia.
British journal of haematology 1980;46(1):7-13.